Our pioneering LiDia-SEQ™ DNA system will be able to test for a range of diseases and will provide vital, actionable information to clinicians at the point-of-need, helping save patients’ lives.
VERSATILE SYSTEM
LiDia-SEQ™ combines powerful analytical capability and accurate results with speed and simplicity of use.
Diagnostic tests are in development for multiple healthcare applications where rapid point-of-need diagnostics are of critical need:
- Bloodstream infection pathogen identification
- Antimicrobial resistance
- Viral and pandemic
- Liquid biopsy for diagnostics and monitoring
SIMPLE
Easy to operate
providing 24/7
diagnostics
FAST
Results in a few hours
at the point of need
ACCURATE
Highly sensitive and
specific
For Research Use Only. Not for use in diagnostic procedures. For illustrative purposes only.
OUR LEADING PROGRAM – Sepsis/BSI and AMR
DNAe’s initial focus is on developing infectious disease diagnostics, where speed and DNA sequence information can make the difference between life and death. This includes a range of tests, starting with a groundbreaking test for bloodstream infections (BSI) and antimicrobial resistance (AMR), which uses whole blood specimens to detect and identify infections that lead to sepsis.
The diagnostic will rapidly identify what infection a patient has, as well as any associated antimicrobial resistance. This will provide clinicians with actionable information to help select the appropriate antibiotics to treat the disease.
Sepsis
As drug resistant bacteria become more common, so will deaths from life-threatening infections like sepsis, which is the body’s unregulated immune response to a severe bloodstream infection. Sepsis is a medical emergency that requires rapid diagnosis and treatment. Sepsis can lead to multiple organ failure and even death if not recognised and treated promptly.
Despite the best antibiotics and intensive care, sepsis is the primary cause of death from infection. Every three seconds, someone in the world dies of sepsis; globally sepsis claims 11 million lives a year4. Sepsis cases are increasing, up by between 8% and 13% over the last decade, claiming more lives than bowel and breast cancer combined.
- Every 3 seconds someone dies of sepsis
- 5,600 people diagnosed with sepsis every hour
- 1,255 people die every hour
- 49M people diagnosed every year
- 11M sepsis-related deaths every year
2 Million
Sepsis cases a year
in the US alone
30-50%
fatality rate
$38.2 BILLION
in treatment
costs a year
The $ value is US only, global figure not readily available.
Dialog with over 100 practicing clinicians and lab directors has confirmed the potential value and impact of LiDia-SEQ™ in combating sepsis. As a result, our semiconductor sequencing platform will launch initially with a groundbreaking test for BSI and AMR, which uses whole blood specimens to detect and identify infections that lead to sepsis.
By rapidly identifying what infection a patient has, as well as any associated AMR, our test will provide clinicians with actionable information to help them select the best antibiotics to target the disease.
It usually takes between 2-6 days to diagnose BSI using a blood culture, depending on whether the microbe is bacterial or fungal, during which time clinicians have only empirical treatment options.
DNAe’s BSI/AMR test takes approximately a work shift to complete and with regulatory clearance can deliver actionable results to the clinician at the point-of-need.
FOCUSED AND FAST
This one breakthrough test is enough to identify a broad range of possible bloodstream infectious organisms, as well as a selection of antimicrobial resistance genes.
As microbial pathogens may be present at very low concentrations in the blood of infected patients (1 colony-forming unit per ml), the BSI/AMR test incorporates a sample preparation stage capable of extracting microbial DNA from a vacutainer of blood, which is subsequently amplified and identified.
Oncology
Also in the development pipeline, DNAe is applying its platform to cancer monitoring. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease7.
DNAe’s integrated, sequencing-based technology will bring genomic analysis to the point-of-need, enabling testing to move out of specialist laboratories and closer to the patient. By detecting and sequencing tumor DNA directly from raw blood samples in a matter of hours, DNAe’s platform has the potential to detect cancer recurrence earlier and response to therapy.
The Company collaborates with leading clinicians and researchers in the field. One such collaboration was awarded a UK Knowledge Transfer Partnership (KTP) by Innovate UK in 2021 which built on existing research partnerships between world experts Professor Coombes, Emeritus Professor of Medical Oncology, Department of Surgery & Cancer – Faculty of Medicine Imperial College and Professor Jacqui Shaw, Head of the Department of Genetics and Genome Biology and Professor of Translational Cancer Genetics at the University of Leicester.
